Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Axsome Therapeutics Acquires AstraZeneca's Epilepsy Candidate in $83 Million Deal

Axsome Therapeutics has made a significant move in the epilepsy treatment space, acquiring AstraZeneca's phase 2 oral GABA receptor modulator through a subsidiary acquisition. The deal, potentially worth over $83 million, marks Axsome's entry into the epilepsy market and bolsters its central nervous system (CNS) portfolio.

NoahAI News11/7/2025

UroGen Terminates Anti-CTLA-4 Partnership with Agenus Following Disappointing Phase 1 Results

In a significant setback for both companies, UroGen Pharmaceuticals has announced the termination of its license agreement with Agenus for the development of zalifrelimab (UGN-301), an anti-CTLA-4 antibody intended for the treatment of urinary tract cancers. The decision comes after phase 1 data failed to meet UroGen's internal benchmarks for advancement to phase 2 trials.

NoahAI News11/7/2025

Cigna Reshuffles Executive Leadership Amidst Industry Challenges

Cigna, one of the largest health insurance providers in the United States, has announced significant changes to its executive leadership team. These moves come as the company, along with the broader healthcare industry, faces increasing scrutiny over rising costs and consumer dissatisfaction.

NoahAI News11/7/2025

Incyte Expands Patient Support Program to Hidradenitis Suppurativa Ahead of FDA Filing

Incyte, a leading pharmaceutical company, has announced the expansion of its Incyte Ingenuity Awards program to include hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This strategic move comes as the company prepares for regulatory filings of its JAK1 inhibitor, povorcitinib, potentially the first oral treatment for HS.

NoahAI News11/7/2025

Cencora Commits $1 Billion to Bolster US Pharmaceutical Distribution Infrastructure

Cencora, the pharmaceutical distribution giant formerly known as AmerisourceBergen, has announced a substantial $1 billion investment plan to expand its operations across the United States over the next five years. This strategic move aims to enhance the company's distribution capacity, improve efficiency, and strengthen supply chain resilience in an evolving pharmaceutical landscape.

NoahAI News11/7/2025

Moderna's Norovirus Vaccine Trial Faces Setbacks and Delays

Moderna's phase 3 trial for its trivalent norovirus vaccine, mRNA-1403, has encountered significant challenges, leading to delays in the study's completion and potential readout. The mRNA specialist's efforts to develop a vaccine against the highly contagious stomach bug have been hampered by multiple obstacles, including a temporary clinical hold and difficulties in accruing sufficient cases.

NoahAI News11/7/2025

Registrar Corp. Expands Global Reach with Acquisition of CMC Medical Devices

Registrar Corp., a U.S.-based compliance specialist and unit of Paine Schwartz Partners, has announced the acquisition of Spanish medical device consulting services provider CMC Medical Devices. This strategic move aims to bolster Registrar's global compliance offering and extend its reach in the medical device and in vitro diagnostic regulation markets.

NoahAI News11/7/2025

Optain Health Acquires EyePACS, Expanding AI-Powered Retinal Screening in Primary Care

Optain Health, a startup specializing in artificial intelligence-powered retinal screening technology, has acquired EyePACS, a teleophthalmology network provider. This strategic move aims to broaden access to eye disease screening in primary care settings across the United States and globally.

NoahAI News11/7/2025

Evommune Heads to NYSE with $150M IPO, Signaling Biotech Market Recovery

Inflammation-focused biotech company Evommune is set to make its public debut on the New York Stock Exchange, marking a significant development in the pharmaceutical industry's financial landscape. The California-based firm's initial public offering (IPO) comes on the heels of MapLight Therapeutics' successful market entry, potentially indicating a thawing of the previously frozen IPO market.

NoahAI News11/7/2025

FDA Approves J&J's Darzalex as First Treatment for Smoldering Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's Darzalex subcutaneous formulation for the treatment of high-risk smoldering multiple myeloma (SMM), marking a significant milestone in the management of this precursor condition to multiple myeloma (MM). This decision represents the first-ever approved treatment for SMM, offering a new option for patients who previously could only be monitored for disease progression.

NoahAI News11/7/2025

FDA Unveils Second Round of National Priority Voucher Recipients, Including Obesity Drug Leaders

The U.S. Food and Drug Administration (FDA) has announced the second batch of recipients for its new "national priority voucher" program, highlighting a continued focus on expediting the development and approval of drugs addressing critical health needs. The latest round of vouchers includes notable entries in the obesity treatment space, as well as therapies for cancer, tuberculosis, and sickle cell disease.

NoahAI News11/7/2025

UroGen Terminates Anti-CTLA-4 Drug License with Agenus, Citing Underwhelming Phase 1 Results

UroGen Pharmaceuticals has announced the termination of its license agreement with Agenus for the anti-CTLA-4 antibody zalifrelimab (UGN-301), following disappointing results from a phase 1 dose-escalation study in bladder cancer. The decision marks a setback for both companies and highlights the challenges faced in developing novel immunotherapies for urinary tract cancers.

NoahAI News11/6/2025

«1...39 40 41...67 »